Justin Kao

Partner

2021 - Current

Partner

2020 - 2021

Co-Founder and Chief Business Officer

2015 - 2020

Helix is dedicated to empowering every person to improve their life through DNA. We believe DNA will be digitally accessible to each person so that it can be used—at any time—to improve health outcomes and accelerate research. To accomplish this, Helix powers life-changing population health programs with health systems and researchers. Helix’s end-to-end solution enables health systems to integrate genomic information on a population scale to improve outcomes, lower costs, and increase patient engagement. Additionally, Helix stores and protects each person's DNA information so that the genome can be continually used in a variety of settings, on-demand, rather than always being a one-time test. The foundation is Helix's world-class clinical laboratory platform and proprietary Exome+™ assay - a panel-grade clinical exome enhanced by more than 300,000 informative non-coding regions. In response to the COVID-19 pandemic, Helix is also providing rapid-turnaround, high quality diagnostic testing for SARS-COV-2 and was selected by the NIH to be a west coast "megalab." We support some of the largest testing providers in the country, including providers, health systems, drive-through sites, and state or local governments. We are a fast-growing startup in the Bay Area, looking for talent in multiple areas. Please visit www.helix.com for more details, or view career opportunities at http://www.helix.com/careers/

Vice President, Healthcare

2010 - 2015

VP in the Healthcare Group, focusing on growth investments in healthcare companies. Investments included JHP Pharmaceuticals (acquired by Par Pharmaceuticals), Silk Road Medical (NASDAQ:SILK), Constitution Medical (acquired by Roche Diagnostics), Accriva Diagnostics (acquired by Werfen), Outset Medical (NASDAQ:OM), Singular Bio (acquired by Invitae), and SOC Telemed (NASDAQ:TLMD). Warburg Pincus is a leading global private equity firm. The firm has more than $35 billion in assets under management. Its active portfolio of more than 125 companies is highly diversified by stage, sector and geography. Warburg Pincus is a growth investor and an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 13 private equity funds that have invested more than $45 billion in over 675 companies in more than 35 countries.

Intern, Corporate Development

2009 - 2009

- Built valuation model and supported diligence for $851M Proteolix acquisition, which ultimately was the main value driver behind $10.4B acquisition of Onyx by Amgen - Developed potential expansion strategy for Onyx outside of oncology, focusing on pipeline products in hepatology and inflammation, and presented findings to Onyx Executive Team

Summer Associate

2008 - 2008

Summer Associate in IP Litigation and Life Sciences

Associate

2005 - 2007

Worked with healthcare and tech clients on a variety of projects, including: - Modeled patient access to cancer drugs for large biotech client and modified $200M Patient Assistance Program to increase patient access while cutting costs - Led post-merger integration for $300M acquisition in software industry and developed M&A “playbook” for client - Grew national nonprofit health organization to $100M in California by analyzing demographic trends, identifying high-impact areas of outreach, and improving fundraisers and special events - Developed market entry strategy for client considering major acquisition in contact lens market